Aktienanalyse zu BridgeBio Pharma, Inc. (BBIO)BBIOBridgeBio Pharma, Inc.

BridgeBio Pharma, Inc. is a biopharmaceutical company. It discovers, creates, tests, and delivers transformative medicines to treat patients who suffer from genetic diseases. Its pipeline of development programs ranges from early science to advanced clinical trials, which includes Attruby, an oral small molecule near-complete transthyretin (TTR) stabilizer, for the treatment of cardiomyopathy of wild-type or variant transthyretin-mediated amyloidosis (ATTR-CM); Beyonttra for the treatment of TTR Amyloidosis; Low-dose Infigratinib, an oral FGFR1-3 selective tyrosine kinase inhibitor (TKI) for the treatment of children with achondroplasia and hypochondroplasia; Encaleret, an oral small molecule antagonist of the calcium sensing receptor (CaSR) that it is developing for the treatment of Autosomal Dominant Hypocalcemia Type 1 (ADH1), and BBP-418, for the treatment of Limb Girdle Muscular Dystrophy Type 2I. It also conducting a Phase 1/2 study (CANaspire) for BBP-812 for Canavan disease. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

BridgeBio Pharma Inc is currently trading at $65.35, significantly below analyst price targets ranging from $94 to $156, indicating potential upside. However, the RSI is at 36.897, suggesting the stock is oversold, and the recent 5-day change is -2.83%, reflecting a downward trend. The main risk is the negative net income, which stands at -$152,216,000 for Q2 2026, indicating ongoing financial challenges. Given the mixed signals, it may be prudent to hold rather than buy at this time.